ArticleBlood advances2020
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.Blood advances · 2026Trial
- Intensity of conditioning but not measurable residual disease status affects the outcomes of umbilical cord blood transplantation.Blood advances · 2026Article
- Cryopreservation and Thawing ofJournal of hematology · 2026Article
- Article
- Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.Journal of the Egyptian National Cancer Institute · 2024Review
- Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation.Blood advances · 2024Article
- Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.Nature reviews. Drug discovery · 2023Review
- Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia.Blood advances · 2023Article
- Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.Bone marrow transplantation · 2023Article
- Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?Bone marrow transplantation · 2023Article
- T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy.Blood advances · 2023Article
- Unrelated Donor Cord Blood Transplantation in Children: Lessons Learned Over 3 Decades.Stem cells translational medicine · 2023Article
- Features of the TCR repertoire associate with patients' clinical and molecular characteristics in acute myeloid leukemia.Frontiers in immunology · 2023Article
- Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior OS for patients with long-term survival.Stem cell research & therapy · 2022Article
- Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia.Leukemia · 2022Article
- Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.Bone marrow transplantation · 2022Article
- Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.Bone marrow transplantation · 2022Article
- Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.Frontiers in oncology · 2022Review
- Controversies and expectations for the prevention of GVHD: A biological and clinical perspective.Frontiers in immunology · 2022Review
- The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.Bone marrow transplantation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared outcomes among adult matched related donor (MRD) patients undergoing peripheral blood stem cell transplantation and adult patients undergoing double unit cord blood transplantation (CBT) at our center between 2010 and 2017. A total of 190 CBT patients were compared with 123 MRD patients. Median follow-up was 896 days (range, 169-3350) among surviving CBT patients and 1262 days (range, 249-3327) among surviving MRD patients. Comparing all CBT with all MRD patients, overall survival (OS) was comparable (P = .61) and graft-versus-host disease (GVHD) relapse-free survival (GRFS) was significantly improved among CBT patients (P = .0056), primarily because of decreased moderate to severe chronic GVHD following CBT (P < .0001; hazard ratio [HR], 3.99; 95% confidence interval [CI], 2.26-7.04). Among patients undergoing our most commonly used MRD and umbilical cord blood (CB) myeloablative regimens, OS was comparable (P = .136) and GRFS was significantly improved among CBT patients (P = .006). Cumulative incidence of relapse trended toward decreased in the CBT group (P = .075; HR, 1.85; CI 0.94-3.67), whereas transplant-related mortality (TRM) was comparable (P = .55; HR, 0.75; CI, 0.29-1.95). Among patients undergoing our most commonly used nonmyeloablative regimens, OS and GRFS were comparable (P = .158 and P = .697). Cumulative incidence of both relapse and TRM were comparable (P = .32; HR, 1.35; CI, 0.75-2.5 for relapse and P = .14; HR, 0.482; CI, 0.18-1.23 for TRM). Our outcomes support the efficacy of CBT and suggest that among patients able to tolerate more intensive conditioning regimens at high risk for relapse, CB may be the preferred donor source.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.